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Abstract
Primary breast lymphoma is a rare entity and carries poor prognosis, bilateral breast lymphoma is even rarer and 
carries worst prognosis. Bilateral breast lymphoma is a rare disease and lacks treatment. Out of the 2766 cases of non-
Hodgkin’s lymphoma registered at our institute from 1994 to 2013, 31 cases of breast lymphoma were found, of which 
four cases had bilateral involvement. In this review, we describe clinical presentation, histopathological subtypes, 
treatment administered and outcome of those four cases retrospectively. All patients were female with a median age 
of 31 years (range 24–64 years). Three patients were diagnosed with diffuse large B-cell lymphoma and mucosa-
associated lymphoid tissue lymphoma detected in one patient. Chemotherapy remained the main treatment modality 
and surgery (excision biopsy) was reserved for diagnostic purpose only, none of the patients received radiation therapy.
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Introduction
Primary breast lymphoma (PBL) is a rare form of breast 
malignancy and accounting 0.4–0.5% of all breast cancers 
and 1.7–2.2% of extranodal non-Hodgkin’s lymphoma 
(NHL).[1] PBLs are classified as disease confined to 
the breast only in the absence of previously existing 
lymphoma.[2] According to Wiseman and Liao criteria, 
PBL is defined by the presence of following features: 
(1) Breast should be the primary site, (2) there should be 
no evidence of the distant organ involvement, (3) tissue 
sample should be adequate and (4) there should be a 
close association between breast tissue and lymphoma.[3] 
According to this definition, lymphoma confined to the 
breast alone will be classified as PBL. However, some 
researchers would also category PBL when bone marrow 
is involved in addition to lymphoma in the breast.[4] 
Bilateral breast lymphoma accounts for about 11% of 
lymphoma involving the breast, whereas a study of 204 
primary diffuse large B-cell lymphoma (DLBCL) patients 
by Ryan et al. showed bilateral breast involvement 
by lymphoma in only 5% of cases.[5,6] Cancer registry 
at Shaukat Khanum Memorial Cancer Hospital and 
Research Centre (SKMCH and RC), Lahore, recorded 
12,866 cases of breast cancer between December 1994 
and December 2013. Amongst those patients, four cases 
of PBL were identified whose details are given in this 
case report.
Materials and Methods
Data on four PBL patients treated at SKMCH and RC 
were collected by review of their case notes using 
hospital electronic medical records in a retrospective 
manner. Following patient variables searched: 
Patients’ demographics such as age and gender, 
presenting clinical symptoms such as B-symptoms and 
pathological characteristics such as histopathology and 
immunohistochemistry of breast biopsy as well as bone 
marrow infiltration and its response to chemotherapy if 
positive at baseline, details of treatment and measurement 
of outcome. A formal ethical approval was obtained from 
the institutional review board.
Case Series
Baseline patient characteristics are shown in Table 1. All 
patients were female, median age at the time of diagnosis 
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was 31 years (range 24–64 years). All patients underwent 
breast ultrasound, mammogram, bone marrow biopsy 
and whole-body computed tomography for staging of 
lymphoma at presentation. Diagnosis was made on 
review of the blocks as all four patients had undergone 
lumpectomy at peripheral hospitals before being referred 
to our institute for further. Ann Arbor system was used for 
staging of lymphoma according to which bilateral cases 
were classified as Stage IVE due to poor prognosis and 
according to Wiseman and Liao criteria.[3]
At presentation, one patient has multiple bilateral skin 
nodules and two were diagnosed with pregnancy/
lactation-associated breast lumps. Two of our patients 
had B symptoms and another two had bone marrow 
involvement at baseline. Histopathological diagnosis 
of DLBCL was made in three patients and one case had 
morphology consistent with mucosa-associated lymphoid 
tissue (MALT) lymphoma. Immunohistochemistry 
consistent with the given diagnosis was the positivity 
of CD 20, CD 30 and Ki 67 in three cases; however, 
immunohistochemistry was unknown for a single patient. 
There was no distant organ involvement at the time of 
presentation in all four cases.
The main stay of treatment was R-CHOP chemotherapy 
(rituximab, cyclophosphamide, doxorubicin, vincristine 
and prednisolone). Surgery was limited for diagnostic 
purpose only, none of our patients received radiation 
therapy to breast. Response to the treatment was assessed 
by bone marrow biopsy after chemotherapy and PET 
scan. One patient died during the chemotherapy and the 
second patient had complete response, while rest of the 
two patients had progressive disease after chemotherapy, 
none of the patient received extensive surgery or radiation 
therapy, survival period ranges from 1 to 13 months; three 
patients died and two were lymphoma specific deaths 
[Table 2].
Discussion
PBL is a rare entity, it represents 0.04–0.5% of all breast 
malignancies.[6] Breast lymphomas are staged according 
to Ann Arbor staging system, although staging of 
bilateral PBL is still controversial, Ryan et al. classified 
bilateral PBL in Stage IVE,[5] this was the largest study of 
PB-DLBCL; they reviewed retrospectively 204 patients, 
whereas other studies include in Stage IE and IIE.[7,8] We 
included bilateral involvement in Stage IVE as they had 
poor prognosis. Bilateral PBLs have some association with 
pregnancy as mentioned in some studies.[9] It is difficult 
to differentiate radiologically between breast lymphoma, 
fibroadenoma and breast cancer.[1,10]
The most common subtype is DLBCL accounts for 
about 50% of all BCLs, other rare types include MALT 
lymphoma, Burkitt lymphoma, anaplastic and follicular, 
small lymphocytic.[11] Aggressive form of PBL is known 
Table 1: Demographics





1 27 DLBCL No Positive Negative Pregnancy associated 
2 35 DLBCL No Negative Negative Multiple skin lesions 
3 64 MALT lymphoma Yes Positive Positive None 
4 24 DLBCL Yes Negative Negative Lactation associated 
MALT: Mucosa‑associated lymphoid tissue, DLBCL: Diffuse large B‑cell lymphoma
Table 2: Treatment and outcome
Case Chemotherapy Radiotherapy Response Local relapse Distant relapse Outcome 
1 R‑CHOP X 6 No PR No No Dead 
2 R‑CHOP X 6 No CR No No Dead 
3 R‑CHOP X 5 No Progressive No No Dead 
4 R‑CHOP X 4, RICE X 5 No Progressive No No Alive 
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to have association with younger age group; three of our 
patients were young.[12]
Another largest study by Jeanneret-Sozzi et al. included 
a review of 84 cases of PBL from 20 institutions, they 
concluded that PBL has better prognosis if managed by 
combined chemotherapy and radiotherapy.[13] MALT 
lymphoma breast is an extremely rare entity amongst the 
NHL, and bilateral involvement is even rarer, we found 
only single patient with bilateral MALT lymphoma.[14]
Chemotherapy stays the main treatment modality for 
breast lymphomas; R-CHOP is the preferred regime, as it 
increases 5-year survival. Aviv et al. recommended addition 
of Rituximab to chemotherapy may reduce central nervous 
system relapse and may be given intrathecal injections,[2,15] 
whereas other studies describe it as ineffective.[16] 
Radiotherapy can be combined with chemotherapy, but the 
role of surgery is limited only to diagnosis and palliation of 
symptoms in progressive disease. Jennings et al. observed 
high mortality rate in patients undergoing mastectomy and 
axillary dissection; therefore, they concluded that there is 
no role of axillary lymph nodal dissection and extensive 
surgery for breast lymphoma.[17,18]
Conclusion
Bilateral breast lymphoma is very rare, but aggressive disease 
with poor prognosis usually present at younger age group, 
aggressive treatment with chemotherapy should be considered 
and surgery should be reserved for diagnosis and palliation.
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